BioSphere Medical to Present at CIRSE 2007 Conference

ROCKLAND, Mass.--(BUSINESS WIRE)--BioSphere Medical, Inc. (NASDAQ: BSMD) (“BioSphere”), the medical device company that pioneered the use of bioengineered microspheres to treat uterine fibroids, hypervascularized tumors and vascular malformations by a procedure called embolization, today announced its sponsorship of a symposium featuring four leading physicians who each plan to discuss their experience with BioSphere's proprietary platform of interventional oncology embolic products. The symposium, entitled “New Embolization Therapies to Treat Liver Cancer,” along with additional scientific presentations by or regarding BioSphere and its products, will take place at this year’s Cardiovascular and Interventional Radiological Society of Europe (CIRSE) Annual Meeting, which is being held September 8-12 in Athens, Greece.

“New Embolization Therapies to Treat Liver Cancer”

“New Embolization Therapies to Treat Liver Cancer” will be held on Tuesday, September 11 from 11:30 a.m. to 12:30 p.m., local time. The symposium will be chaired by Jafar Golzarian, MD, and will feature the following presentations:

• “Japanese Experience with HepaSphere/Super Absorbent Polymer (SAP–MS)” by Shinichi Hori, MD, from Osaka, Japan, the inventor and licensor of BioSphere’s HepaSphere™ Microspheres (“HepaSphere”). Dr. Hori has used HepaSphere in Japan to treat primary and metastatic liver cancer.
• “European Experience with HepaSphere” by Mark Ryan, MD. Dr. Ryan will speak about HepaSphere on behalf of European investigators.
• “U.S. Experience with QuadraSphere” by Stephen Kee, MD. Dr. Kee will focus on his initial experience with BioSphere’s QuadraSphere™ Microspheres (“QuadraSphere”).
• “Bevacizumab Combined with TACE for HCC” by Jeff Geschwind, MD, Director, Vascular and Interventional Radiology at The Johns Hopkins University School of Medicine. Dr. Geschwind will discuss his initial experience with chemoembolization therapy utilizing BioSphere’s patented Embosphere® Microspheres in combination with Avastin® (bevacizumab). As previously announced, Dr. Geschwind is conducting a Phase II, two-year, single-arm clinical study to treat patients with primary liver cancer combining, for the first time, Avastin and Embosphere Microspheres.

Richard Faleschini, President and Chief Executive Officer of BioSphere Medical, commented, "Maintaining a consistent podium presence at events such as CIRSE – which is one of the key gatherings for interventional radiologists from around the world – is a vital element of BioSphere’s overall growth strategy, specifically in the area of interventional oncology. CIRSE 2007 will assist us in introducing new data related to the use of our platform of interventional oncology products which, we believe, may further advance the treatment of conditions such as primary liver cancer, hypervascularized tumors and arteriovenous malformations. Additionally, if merited, presentations such as these can evolve from the podium to peer-reviewed publications. Journal publication of the results discussed in any such presentations has the potential to catalyze physician acceptance of new embolics such as HepaSphere and QuadraSphere, which is the initial phase of clinical adoption and commercialization.”

About CIRSE

The Cardiovascular and Interventional Radiological Society of Europe is a nonprofit, educational and scientific association, which represents physicians and scientists with an active personal involvement and interest in interventional radiology or cardiovascular imaging techniques. CIRSE is home to more than 2,300 interventional professionals across Europe and abroad.

About BioSphere Medical, Inc.

BioSphere Medical, Inc., a medical device company based in Rockland, Massachusetts, seeks to pioneer and commercialize minimally invasive diagnostic and therapeutic applications based on proprietary bioengineered microsphere technology. The Company's core technologies, patented bioengineered polymers and manufacturing methods, are used to produce microscopic spherical materials with unique beneficial properties for a variety of medical applications. BioSphere's principal focus is the treatment of symptomatic uterine fibroids using a procedure called uterine fibroid embolization, or UFE. The Company's products continue to gain acceptance in this rapidly emerging procedure as well as in a number of other new and established medical treatments.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements concerning the effect of CIRSE participation on the Company’s growth strategy, the potential for presentations regarding the Company’s products to be further discussed in journal publications, and the potential benefits of such publications on physician acceptance. There are important risks and uncertainties which could cause actual results to differ from those contained in such forward-looking statements, including that: the Company may be unable to gain market acceptance for its products and products under development, such as its products for interventional oncology and UFE; the Company may not achieve the growth strategies it has sought to implement; the Company may not obtain and maintain all of the regulatory approvals, domestically and abroad, needed to develop and commercialize its products; the Company may face intense competition and risks relating to its ability to maintain patent protection for its products and products under development; the Company may be unable to generate the additional capital necessary to grow its business; and, the Company’s business may be adversely affected by general market conditions. For a further discussion of these and other risks facing the Company, see "Risk Factors" in BioSphere’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2007, as filed by the Company with the Securities and Exchange Commission, and described in other filings made by the Company from time to time with the Securities and Exchange Commission. The forward-looking statements in this press release are made as of the date of this press release and the Company disclaims any obligation to update these forward-looking statements as a result of changed events, circumstances or otherwise.